Phio Pharmaceuticals
PHIO
14 hedge funds and large institutions have $415K invested in Phio Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
17% more funds holding
Funds holding: 12 → 14 (+2)
0% less ownership
Funds ownership: 0.05% → 0.05% (-0%)
25% less capital invested
Capital invested by funds: $551K → $415K (-$136K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$12.8K |
| 2 |
E
Ergoteles
New York
|
+$8.71K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$8.48K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.04K |
| 5 |
VF
Virtu Financial
New York
|
+$2.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$56K |
| 2 |
Renaissance Technologies
New York
|
-$14.9K |
| 3 |
Two Sigma Investments
New York
|
-$3.18K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.89K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$303 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $125K | -$56K | -739 | -27% |
|
|
2
Renaissance Technologies
New York
| $122K | -$14.9K | -197 | -9% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $61K | – | – | – |
|
4
Cetera Investment Advisers
Schaumburg,
Illinois
| $43K | – | – | – |
|
|
5
Two Sigma Investments
New York
| $13K | -$3.18K | -42 | -16% |
|
|
TSS
6
Two Sigma Securities
New York
| $13K | +$8.48K | +112 | +118% |
|
|
VF
7
Virtu Financial
New York
| $11K | +$2.88K | +38 | +27% |
|
|
HF
8
HRT Financial
New York
| $10K | +$12.8K | +169 | New |
|
|
E
9
Ergoteles
New York
| $7K | +$8.71K | +115 | New |
|
|
10
Balyasny Asset Management
Chicago,
Illinois
| $6K | +$7.04K | +93 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $3K | -$1.89K | -25 | -33% |
|
12
Morgan Stanley
New York
| $1K | – | – | – |
|
|
13
Simplex Trading
Chicago,
Illinois
| – | -$303 | -4 | Closed |
|
PHIO Hedge Fund Activity: Q3 2022 in Review
14 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2022, worth a combined $415K — down 25% from $551K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PHIO positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $12.8K. The largest seller was Vanguard Group, cutting an estimated $56K.
- 14 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2022, up from 12 in Q2 2022.
- Funds reported $415K of Phio Pharmaceuticals stock for Q3 2022, down 25% quarter-over-quarter.
- 3 funds opened new Phio Pharmaceuticals positions in Q3 2022 and 1 closed out, a net change of +2 holders.
- The largest Phio Pharmaceuticals buyer in Q3 2022 was HRT Financial, an estimated $12.8K added.
- The largest Phio Pharmaceuticals seller in Q3 2022 was Vanguard Group, an estimated $56K sold.
Based on aggregated 13F filings for Q3 2022.